Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop cancer cells from dividing so they stop growing or
die. Combining combination chemotherapy with monoclonal antibody therapy may kill more cancer
cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab and combination chemotherapy
in treating patients who have relapsed or refractory large cell lymphoma.